Literature DB >> 24719068

Periorbital hyperpigmentation: review of etiology, medical evaluation, and aesthetic treatment.

Wendy E Roberts.   

Abstract

Periorbital hyperpigmentation (POH) is a common worldwide problem. It is challenging to treat, complex in pathogenesis, and lacking straightforward and repeatable therapeutic options. It may occur in the young and old, however the development of dark circles under the eyes in any age is of great aesthetic concern because it may depict the individual as sad, tired, stressed, and old. While "dark circles" are seen in all skin types, POH is often more commonly seen in skin of color patients worldwide. With a shifting US demographic characterized by growing number of aging patients as well as skin of color patients, we will encounter POH with greater frequency. As forecasted by the US Census, by 2030 1 in 5 Americans will be 65 plus years old and greater than 50% of the population will possess ethnic skin of color. The disparity in the medical community's understanding of POH versus popular demand for treatment is best illustrated when you have only 65 cited articles to date indexed on PubMed line compared to the 150,000,000 results on Google search engine. Most importantly POH may be a final common pathway of dermatitis, allergy, systemic disorders, sleep disturbances, or nutritional deficiences that lends itself to medical, surgical, and cosmeceutical treatments. A complete medical history with ROS and physical examination is encouraged prior to treating the aesthetic component. Sun protection is a cornerstone of therapy. Safety issues are of utmost concern when embarking upon treatments such as chemical peeling, filler injection, and laser therapy as not to worsen the pigmentation. Without intervention, POH usually progresses over time so early intervention and management is encouraged. The objective of this study was to review the current body of knowledge on POH, provide the clinician with a guide to the evaluation and treatment of POH, and to present diverse clinical cases of POH that have responded to different therapies including non-ablative fractional photothermolysis in two skin of color patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24719068

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  8 in total

Review 1.  The Tricky Tear Trough: A Review of Topical Cosmeceuticals for Periorbital Skin Rejuvenation.

Authors:  Stacey J Pilkington; Sarah Belden; Richard A Miller
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  Comparison of carboxy therapy and fractional Q-switched ND:YAG laser on periorbital dark circles treatment: a clinical trial.

Authors:  Mohammad Ali Nilforoushzadeh; Maryam Heidari-Kharaji; Shiva Alavi; Sara Zolghadr; Mona Mahmoudbeyk; Nahid Nikkhah
Journal:  Lasers Med Sci       Date:  2021-02-27       Impact factor: 3.161

3.  Periorbital Hyperpigmentation in Patients with Xanthelasma Palpebrarum: An Interesting Observation.

Authors:  Eftychia Platsidaki; Anargyros Kouris; Efthymia Agiasofitou; Christina Antoniou; Georgios Kontochristopoulos
Journal:  J Clin Aesthet Dermatol       Date:  2016-04-01

4.  Effectiveness and Safety of Topical Under-eye Serum in Patients with Periorbital Hyperpigmentation: An Open-label Single Arm Prospective Study.

Authors:  B S Chandrashekar; Soragavi Soumya
Journal:  J Clin Aesthet Dermatol       Date:  2022-02

5.  Infraorbital Dark Circles: A Review of the Pathogenesis, Evaluation and Treatment.

Authors:  Ivan Vrcek; Omar Ozgur; Tanuj Nakra
Journal:  J Cutan Aesthet Surg       Date:  2016 Apr-Jun

6.  Periorbital Hyperpigmentation: What Lies Beneath?

Authors:  Rashmi Sarkar; Anupam Das
Journal:  Indian Dermatol Online J       Date:  2018 Jul-Aug

7.  Periorbital aesthetic concerns in patients seeking corneal refractive surgery.

Authors:  Milind N Naik; Mohammed A Khader; Somasheila I Murthy
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

Review 8.  Recommendations for the treatment of tear trough deformity with cross-linked hyaluronic acid filler.

Authors:  Javier Anido; José Manuel Fernández; Ignacio Genol; Natalia Ribé; Gema Pérez Sevilla
Journal:  J Cosmet Dermatol       Date:  2020-08-26       Impact factor: 2.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.